Biohaven Ltd (BHVN)

$9.16 -0.23 (-2.45%)
Market Cap 1.39B
Revenue (ttm) 0.00
Net Income (ttm) -738.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 4.59
Volume 799,695
Avg Vol 2,302,984
Day's Range N/A - N/A
Shares Out 150.42M
Stochastic %K 64%
Beta 1.34
Analysts Strong Sell
Price Target $22.75

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinica...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
PrestigeStoner
PrestigeStoner Apr. 9 at 4:55 PM
$BHVN I got sick to my stomach today I had to sell 26,000 shares to close on our new house. Sold them way to low because I had to. I still have 24,000 shares.
1 · Reply
Timefortendies77
Timefortendies77 Apr. 8 at 10:41 AM
$BHVN 8s yesterday was a gift.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 7 at 4:50 PM
$BHVN We won't have that long to accumulate below 10. Big things happening this year, just requires patience for reward.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 6 at 5:22 PM
$BHVN It's sneaking down to below the tweet Mar 31 about an FDA meeting, giving hope the CRLed drug might eventually be back in play. Back to waiting now to see what happens, and potentially a mention in earnings next month. A sit and wait stock.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 4 at 2:56 PM
$BHVN Thanks to the offering and the 10% buy by Janus we have a general floor in the 9-10 range while we all wait for various updates. The big hit from the CRL happened, so now we are looking for clear skies ahead.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 2 at 8:29 PM
$BHVN Sequence of Events: Nov 5, 2025: Biohaven receives CRL. Dec 3, 2025: Dr. Tracy Beth H becomes CDER Director. Feb 13, 2026: Biohaven CEO Vlad C calls the FDA's decisions a "systemic problem" and "uncooperative". Feb 23, 2026: FDA officially launches the Plausible March 31, 2016: Tweet about BHVN recent meeting with FDA Chief Counsel (posted by a Jeff C referencing BioCentury article) Mechanism Framework to accelerate rare disease approvals. Context: This framework was released after the CEO's public statements. It provides a specific "playbook" for the FDA to approve drugs based on disease biology and natural history data when traditional trials aren't feasible. SUMMARY: SOMETHING IS BREWING AND IF POSITIVE WE SHOULD KNOW SOON (potentially by earnings).
0 · Reply
Timefortendies77
Timefortendies77 Apr. 2 at 4:29 PM
$BHVN Biohaven's Current Strategy: Can It Work? Biohaven is now using the newly formalized Plausible Mechanism Framework (Feb 2026) as the primary basis for its appeal. Is it Sufficient?: The framework allows for approval if a therapy targets a known biological cause and is supported by well-characterized natural history data. Biohaven argues troriluzole fits this perfectly: it targets glutamate (a "plausible mechanism" for neurodegeneration in ataxia) and showed a 50–70% slowing of disease progression compared to historical natural history data. The "Compromise": Biohaven is meeting with the new CDER leadership to argue that their existing data meets the framework's requirements for "substantial evidence of effectiveness" without needing a new eight-year trial.
2 · Reply
erevnon
erevnon Apr. 2 at 3:45 PM
Citigroup maintains Biohaven $BHVN at Buy and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
sellthedip1
sellthedip1 Apr. 2 at 2:47 PM
$BHVN
0 · Reply
mmtiddy
mmtiddy Apr. 2 at 11:32 AM
$BHVN So sexy, today’s market is down bc of orange man, will double down if this tanks
1 · Reply
Latest News on BHVN
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Mar 19, 2026, 7:30 AM EDT - 22 days ago

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 4:05 PM EST - 5 weeks ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 3 months ago

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Jan 7, 2026, 7:00 AM EST - 3 months ago

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

US Stocks Mixed; Biohaven Shares Fall

Dec 26, 2025, 9:45 AM EST - 3 months ago

US Stocks Mixed; Biohaven Shares Fall

Biohaven Misses The Mark In Depression Trial, Stock Falls

Dec 26, 2025, 8:20 AM EST - 3 months ago

Biohaven Misses The Mark In Depression Trial, Stock Falls

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus

Dec 26, 2025, 5:09 AM EST - 3 months ago

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus

IVV SOBR SPXL SPY SSO UPRO VOO

Biohaven's depression drug fails mid-stage trial, shares fall

Dec 24, 2025, 3:24 PM EST - 3 months ago

Biohaven's depression drug fails mid-stage trial, shares fall

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Dec 24, 2025, 1:00 PM EST - 3 months ago

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 7:00 AM EST - 4 months ago

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Nov 13, 2025, 4:05 PM EST - 5 months ago

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Nov 12, 2025, 8:10 AM EST - 5 months ago

FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

FLNG

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Nov 12, 2025, 7:15 AM EST - 5 months ago

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Nov 11, 2025, 4:05 PM EST - 5 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Nov 10, 2025, 6:58 AM EST - 5 months ago

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Nov 5, 2025, 12:53 PM EST - 5 months ago

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven shares plunge after US FDA declines to approve brain disorder drug

Nov 5, 2025, 10:02 AM EST - 5 months ago

Biohaven shares plunge after US FDA declines to approve brain disorder drug

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Nov 4, 2025, 8:06 PM EST - 5 months ago

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVN

Sep 10, 2025, 3:39 PM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

Sep 6, 2025, 10:03 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

Aug 28, 2025, 6:55 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

Aug 22, 2025, 10:05 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Aug 11, 2025, 7:00 AM EDT - 8 months ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN

Aug 4, 2025, 8:45 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 9 months ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 9 months ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Jul 15, 2025, 10:46 AM EDT - 9 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Jun 10, 2025, 2:00 PM EDT - 10 months ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

PrestigeStoner
PrestigeStoner Apr. 9 at 4:55 PM
$BHVN I got sick to my stomach today I had to sell 26,000 shares to close on our new house. Sold them way to low because I had to. I still have 24,000 shares.
1 · Reply
Timefortendies77
Timefortendies77 Apr. 8 at 10:41 AM
$BHVN 8s yesterday was a gift.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 7 at 4:50 PM
$BHVN We won't have that long to accumulate below 10. Big things happening this year, just requires patience for reward.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 6 at 5:22 PM
$BHVN It's sneaking down to below the tweet Mar 31 about an FDA meeting, giving hope the CRLed drug might eventually be back in play. Back to waiting now to see what happens, and potentially a mention in earnings next month. A sit and wait stock.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 4 at 2:56 PM
$BHVN Thanks to the offering and the 10% buy by Janus we have a general floor in the 9-10 range while we all wait for various updates. The big hit from the CRL happened, so now we are looking for clear skies ahead.
0 · Reply
Timefortendies77
Timefortendies77 Apr. 2 at 8:29 PM
$BHVN Sequence of Events: Nov 5, 2025: Biohaven receives CRL. Dec 3, 2025: Dr. Tracy Beth H becomes CDER Director. Feb 13, 2026: Biohaven CEO Vlad C calls the FDA's decisions a "systemic problem" and "uncooperative". Feb 23, 2026: FDA officially launches the Plausible March 31, 2016: Tweet about BHVN recent meeting with FDA Chief Counsel (posted by a Jeff C referencing BioCentury article) Mechanism Framework to accelerate rare disease approvals. Context: This framework was released after the CEO's public statements. It provides a specific "playbook" for the FDA to approve drugs based on disease biology and natural history data when traditional trials aren't feasible. SUMMARY: SOMETHING IS BREWING AND IF POSITIVE WE SHOULD KNOW SOON (potentially by earnings).
0 · Reply
Timefortendies77
Timefortendies77 Apr. 2 at 4:29 PM
$BHVN Biohaven's Current Strategy: Can It Work? Biohaven is now using the newly formalized Plausible Mechanism Framework (Feb 2026) as the primary basis for its appeal. Is it Sufficient?: The framework allows for approval if a therapy targets a known biological cause and is supported by well-characterized natural history data. Biohaven argues troriluzole fits this perfectly: it targets glutamate (a "plausible mechanism" for neurodegeneration in ataxia) and showed a 50–70% slowing of disease progression compared to historical natural history data. The "Compromise": Biohaven is meeting with the new CDER leadership to argue that their existing data meets the framework's requirements for "substantial evidence of effectiveness" without needing a new eight-year trial.
2 · Reply
erevnon
erevnon Apr. 2 at 3:45 PM
Citigroup maintains Biohaven $BHVN at Buy and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
sellthedip1
sellthedip1 Apr. 2 at 2:47 PM
$BHVN
0 · Reply
mmtiddy
mmtiddy Apr. 2 at 11:32 AM
$BHVN So sexy, today’s market is down bc of orange man, will double down if this tanks
1 · Reply
Timefortendies77
Timefortendies77 Apr. 2 at 1:42 AM
$BHVN What are the chances do you all think FDA agrees to a path forward and will revist the approval of the drug that got CRLed by the last guy that left FDA? Many companies were mad, and BHVN wants a path forward. Could lift us back again.
1 · Reply
sellthedip1
sellthedip1 Apr. 1 at 9:25 PM
$BHVN not bad
1 · Reply
BapoRothstein
BapoRothstein Apr. 1 at 8:58 PM
$BHVN Happy to hold.
0 · Reply
RunnerSignals
RunnerSignals Apr. 1 at 8:22 PM
market warriors ​$PROP $BHVN $BGL early weakness absorbed but buyers stepped in where it mattered
0 · Reply
Dheeraj_6
Dheeraj_6 Apr. 1 at 8:14 PM
$BHVN I am happy with 15% everyday . If FDA agrees with the path forward and approve the drug,this would fly beyond our imagination. Keep faith and patience , and trust in the management.
0 · Reply
towie
towie Apr. 1 at 4:18 PM
$BHVN what’s causing the move up in Bhvn today? 
0 · Reply
ItSaulGoodMaan
ItSaulGoodMaan Apr. 1 at 3:18 PM
$BHVN
0 · Reply
Timefortendies77
Timefortendies77 Apr. 1 at 3:12 PM
$BHVN So we will get another look at the drug that didn't get approved? What timeframe? Anyone guess?
2 · Reply
mv21970
mv21970 Apr. 1 at 1:40 PM
$BHVN interesting reading, looks like a lot going on behind the scenes at the FDA https://x.com/jeff_cranmer/status/2039127714599440671
0 · Reply
mmtiddy
mmtiddy Mar. 30 at 4:09 PM
$BHVN starting a position here
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 25 at 1:10 AM
$BHVN Share Price: $8.40 Contract Selected: Oct 16, 2026 $11.0 Calls Buy Zone: $0.81 – $1.00 Target Zone: $1.35 – $1.65 Potential Upside: 58% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
sellthedip1
sellthedip1 Mar. 24 at 6:39 PM
$BHVN loading!
1 · Reply